Jensen Investment Management Inc. Lowers Stock Position in Zoetis Inc. $ZTS

Jensen Investment Management Inc. decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 45.3% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 883,924 shares of the company’s stock after selling 731,507 shares during the period. Zoetis makes up approximately 1.6% of Jensen Investment Management Inc.’s investment portfolio, making the stock its 22nd largest holding. Jensen Investment Management Inc. owned 0.20% of Zoetis worth $129,336,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Halbert Hargrove Global Advisors LLC raised its position in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares during the last quarter. NewSquare Capital LLC boosted its holdings in shares of Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the last quarter. Financial Consulate Inc. purchased a new stake in shares of Zoetis in the 3rd quarter valued at $39,000. SJS Investment Consulting Inc. increased its stake in shares of Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after acquiring an additional 257 shares during the period. Finally, TruNorth Capital Management LLC acquired a new stake in shares of Zoetis in the third quarter worth $42,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ZTS. Stifel Nicolaus decreased their target price on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. JPMorgan Chase & Co. lowered their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. HSBC set a $140.00 price objective on Zoetis in a research report on Wednesday, December 10th. Finally, The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a report on Monday, December 15th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $152.45.

Zoetis Stock Up 0.7%

Shares of ZTS opened at $128.13 on Wednesday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The stock has a 50 day moving average price of $124.03 and a 200 day moving average price of $135.84. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.00. The stock has a market capitalization of $56.47 billion, a price-to-earnings ratio of 21.57, a PEG ratio of 2.20 and a beta of 0.96.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 35.69%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.